Filtered By:
Education: Workshops
This page shows you your search results in order of relevance. This is page number 19.
Order by Relevance | Date
Total 303 results found since Jan 2013.
Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases
Vaccine. 2021 Aug 5:S0264-410X(21)00964-6. doi: 10.1016/j.vaccine.2021.07.071. Online ahead of print.ABSTRACTModern vaccinology has experienced major conceptual and technological advances over the past 30 years. These include atomic-level structures driving immunogen design, new vaccine delivery methods, powerful adjuvants, and novel animal models. In addition, utilizing advanced assays to learn how the immune system senses a pathogen and orchestrates protective immunity has been critical in the design of effective vaccines and therapeutics. The National Institute of Allergy and Infectious Diseases of the National Institut...
Source: Vaccine - August 9, 2021 Category: Allergy & Immunology Authors: M Patricia D'Souza Amy C Palin Thomas Calder Hana Golding Steven H Kleinstein Erin L Milliken David O'Connor Georgia Tomaras Jon Warren Cesar Boggiano Source Type: research
The Crossroads of Glycoscience, Infection, and Immunology
Advances in experimental capabilities in the glycosciences offer expanding opportunities for discovery in the broad areas of immunology and microbiology. These two disciplines overlap when microbial infection stimulates host immune responses and glycan structures are central in the processes that occur during all such encounters. Microbial glycans mediate host-pathogen interactions by acting as surface receptors or ligands, functioning as virulence factors, impeding host immune responses, or playing other roles in the struggle between host and microbe. In the context of the host, glycosylation drives cell–cell interactio...
Source: Frontiers in Microbiology - September 27, 2021 Category: Microbiology Source Type: research
A Trans-Agency Workshop on the Pathophysiology of Radiation-Induced Lung Injury
Radiat Res. 2021 Oct 29. doi: 10.1667/RADE-21-00153.1. Online ahead of print.ABSTRACTAs of January 2021, the U.S. Food and Drug Administration has approved four radiation exposure medical countermeasures (MCMs) to treat hematological acute effects, but no MCM is yet approved for radiation-induced lung injury (RILI). MCM approval for RILI and other subsyndromes utilizes the FDA Animal Efficacy Rule (Animal Rule), that requires demonstration of MCM efficacy in animal models with well-characterized pathophysiology, therefore, allowing translation to human use. A good animal model replicates the clinical condition and natural ...
Source: Radiation Research - October 29, 2021 Category: Physics Authors: Merriline M Satyamitra David R Cassatt Libero Marzella Source Type: research
Development of Biomarkers for Radiation Biodosimetry and Medical Countermeasures Research: Current Status, Utility, and Regulatory Pathways
Radiat Res. 2021 Dec 8. doi: 10.1667/RADE-21-00157.1. Online ahead of print.ABSTRACTBiomarkers are important indicators of biological processes in health or disease. For this reason, they play a critical role in advanced development of radiation biodosimetry tools and medical countermeasures (MCMs). They can aid in the assessment of radiation exposure level, extent of radiation-induced injury, and/or efficacy of an MCM. This meeting report summarizes the presentations and discussions from the 2020 workshop titled, "Biomarkers in Radiation Biodosimetry and Medical Countermeasures," sponsored by the Radiation and Nuclear Cou...
Source: Radiation Research - December 8, 2021 Category: Physics Authors: Merriline M Satyamitra Andrea L DiCarlo Brynn A Hollingsworth Thomas A Winters Lanyn P Taliaferro Source Type: research
Impressions and Aspirations from the FDA GREAT VI Workshop on Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis and Perspectives for Progress in the Field
The U.S. Food and Drug Administration (FDA) hosted a workshop on July 21, 2021 to discuss the disease characteristics, natural history, and endpoints to assess treatment benefit in patients with eosinophilic gastrointestinal disorders (EGID) beyond eosinophilic esophagitis (EoE). Notably, EGID beyond EoE, such as eosinophilic gastritis, eosinophilic enteritis, and eosinophilic colitis, herein referred to as non-EoE EGID, are understudied relative to EoE. This workshop provided a forum for open discussion among stakeholders —medical professionals (including their societies and research groups), FDA representatives, an ind...
Source: Journal of Allergy and Clinical Immunology - December 21, 2021 Category: Allergy & Immunology Authors: Marc E. Rothenberg, Shawna K.B. Hottinger, Nirmala Gonsalves, Glenn T. Furuta, Margaret H. Collins, Nicholas J. Talley, AC, Kathryn Peterson, Calies Menard-Katcher, Macie Smith, Ikuo Hirano, Robert M. Genta, Mirna Chehade, Sandeep K. Gupta, Jonathan M. Sp Source Type: research
NIH Policies and Regulatory Pathways to U.S. FDA licensure: Strategies to Inform Advancement of Radiation Medical Countermeasures and Biodosimetry Devices
Radiat Res. 2022 Feb 3. doi: 10.1667/RADE-21-00198.1. Online ahead of print.ABSTRACTThe Radiation and Nuclear Countermeasures Program within the National Institute of Allergy and Infectious Diseases (NIAID), is tasked with the mandate of identifying biodosimetry tests to assess exposure and medical countermeasures (MCMs) to mitigate/treat injuries to individuals exposed to significant doses of ionizing radiation from a radiological/nuclear incident, hosted. To fulfill this mandate, the Radiation and Nuclear Countermeasures Program (RNCP), hosted a workshop in 2018 workshop entitled "Policies and Regulatory Pathways to U.S....
Source: Radiation Research - February 3, 2022 Category: Physics Authors: Merriline M Satyamitra Zulmarie Perez-Horta Andrea L DiCarlo David R Cassatt Carmen I Rios Paul W Price Lanyn P Taliaferro Source Type: research
